US · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP
Vitaspring Biomedical Co. Ltd. VSBC
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$0.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 10-year series below
Revenue
Net income
Per share
USD 0.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-2859.3%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.21B
Shares outstanding, FY2025
Change, 5 years−1.3%
Change, 10 years—
The share count shrank 1% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 14,676.00
total assets, end of FY2025
Total assetsUSD 14,676.00
EquityUSD -4.4M
CashUSD 2,084.00
Current ratio0.00×
Equity funds -30189% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.00
0.00
−0.01
−0.02
0.00
0.00
0.00
0.00
0.00
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
108.7
441.4
·
·
·
−1.5
Shares out B
0.21
0.21
·
0.15
0.12
0.21
0.01
0.01
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 32
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 6 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed